Clinoscope Services Limited, a substantial shareholder in Neimeth International Pharmaceuticals Plc, has acquired an additional 40 million ordinary shares in the pharmaceutical company for ₦312 million.
The transaction, executed in Lagos on August 4, 2026, was carried out at ₦7.80 per share, according to a corporate disclosure signed by Neimeth’s Company Secretary, Chinenye S. Adekanmbi, and filed with the Nigerian Exchange Limited (NGX).
The latest purchase extends Clinoscope’s return to the Neimeth market after the investment company significantly reduced its holding in 2025.
In December 2025, Clinoscope disposed of 500 million Neimeth shares at ₦6.00 each, following an earlier sale of 15.3 million shares at ₦6.10 on September 17. The two transactions involved a combined 515.3 million shares valued at approximately ₦3.12 billion.
The disposals reduced Clinoscope’s interest in Neimeth from about 25 per cent to 12.94 per cent, based on the company’s reported shareholding position.
However, Clinoscope subsequently resumed buying Neimeth shares in 2026. On June 30, it acquired 63,553,172 shares at ₦7.79 each in a transaction valued at approximately ₦495.1 million.
The latest acquisition brings Clinoscope’s additional purchases during the period to more than 103.5 million shares, following its substantial reduction in the previous year.
The renewed accumulation comes as Neimeth continues efforts to strengthen its balance sheet and position the company for future growth.
At its 67th Annual General Meeting on June 25, 2026, shareholders approved an additional ₦30 billion capital-raising programme, bringing the total fundraising mandate available to the company to ₦50 billion. The approved programme provides the company with flexibility to raise capital through various instruments and funding structures, subject to applicable regulatory requirements.
Neimeth has also undertaken a capital restructuring exercise aimed at addressing accumulated losses and improving its financial position. Under the approved restructuring, the company reduced its share premium account from approximately ₦2.38 billion to ₦390.02 million, with about ₦1.99 billion transferred to the revenue reserve account.
The restructuring forms part of Neimeth’s broader efforts to repair its capital base and create greater capacity to support its operations and expansion plans.
The company’s shares have also delivered strong returns over the past year. Neimeth gained about 162 per cent in 2025 before experiencing a pullback towards the end of the year, around the period when Clinoscope disposed of its large block of shares.
The stock subsequently recovered. It traded around ₦9.00 in mid-July 2026, while its reported 52-week trading range stood between ₦4.95 and ₦16.15.
Clinoscope’s renewed purchases therefore come at a significant point for Neimeth as the pharmaceutical manufacturer works to strengthen its financial position and secure additional funding for its business plans.
While shareholder purchases do not by themselves guarantee future share-price performance, continued accumulation by a substantial shareholder could provide a positive signal to investors as Neimeth progresses with its capital-raising and balance-sheet restructuring initiatives.
